Media & Resources

NEW YORK – JUNE 27, 2023 – IAVI announced today that the first participants have been vaccinated with a Sudan virus (SUDV) vaccine candidate in a first-in-human Phase 1 clinical trial in the U.S. The IAVI-sponsored trial is funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness…

TB kills 1.6 million people a year, causing more deaths than any other single infectious disease apart from COVID-19, and sickens more than 10 million people annually. A new TB vaccine is needed to reach global END TB goals. MTBVAC is a highly promising vaccine candidate that has the potential to be used as an…

Denmark, represented by the Danish Ministry of Foreign Affairs is committed to contribute a total of DKK 20 million (US$3 million) from 2022-2025.

Funding will allow for additional development and testing of IAVI’s single-dose vaccine candidates against the filoviruses Marburg virus and Sudan ebolavirus.

The Ministry will award IAVI €21 million over the next five years as part of the Product Development Partnership IV Fund.

Scripps Research, IAVI, Fred Hutch, VRC and other collaborators publish study data in Science, helping validate novel vaccination strategy.

Merck will provide the investigational vaccine based on a proven platform technology.

The trial is designed to evaluate the candidate’s safety, tolerability, and immunogenicity.